Eris Lifesciences - Niche Launches to Aid Growth over the Medium Term
The Dydrogesterone market is at an interesting phase, with an improvement in demand due to better access, affordability, and technical superiority...
349 Views
Eris Lifesciences - In Line 4QFY22 at the Operational Level; Geared up for Launches in FY23
ERIS delivered an operationally inline 4QFY22. It ended the second consecutive year with earnings growth in the a healthy teens compared to stable...
366 Views
Mix of Chronic portfolio, rising coverage, and better operating leverage to drive earnings growth
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general...
515 Views
Eris Lifesciences (HOLD): Strong quarter; cut to HOLD post recent rally
Q1 EBITDA/PAT growth strong at 22%/20% YoY to Rs 1.3bn/Rs 1.1bn, meeting street estimates
370 Views
Eris Lifesciences - 2QFY19 – Acquisitions Drive Top Line Much Higher, Bottom Line to Follow by FY20E
Eris Lifesciences (ERIS IN) reported lower than expected performance in 2QFY19. Revenues were 5% lower than our estimates at Rs 2,642 mn. The...
520 Views